Monograph
C01CE02 - Milrinone |
Propably not porphyrinogenic |
PNP |
Rationale
Probably no significant CYP-dependent metabolism. Hydrophilic substance, no data pointing to CYP-affinity.
Chemical description
Bipyridine derivative lactate.
Therapeutic characteristics
Used in acute heart failure. Administered as infusion about 1 mg/kgBW/24 h.
Metabolism and pharmacokinetics
Elimination occurs mainly via the urine; about 83% of a dose is excreted as unchanged drug, about 10% as O-glucuronide. Major metabolic pathways appear to be both oxidative and conjugative (primarily glucuronidation), based on animal studies. Some CYP450-mediated metabolism can therefore not be excluded. No data pointing to CYP-interaction.
Preclinical data
None
Personal communication
None
Published experience
None
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Finland© NAPOS 2024